Last reviewed · How we verify
GLPG2222 50 mg
At a glance
| Generic name | GLPG2222 50 mg |
|---|---|
| Sponsor | Galapagos NV |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Cough
- Sputum increased
- Dyspnoea
- Epistaxis
- Nasal Congestion
- Oropharyngeal pain
- Upper-airway cough syndrome
- Dysphonia
- Pulmonary haemorrhage
- Infective pulmonary exacerbation of cystic fibrosis
- Viral upper respiratory tract infection
- Ear infection
Key clinical trials
- A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222 (PHASE2)
- A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |